Search Results - "Sullivan, Taegen"

Abstract 94: Randomized, Double-blind, Placebo-controlled Phase 1 Study Of Vwf-binding Aptamer, Bb-031: Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Activity In Healthy Volunteers by Nimjee, Shahid M, Wheeler, Debra, Nelson, Stacy, Shea, Richard J, Sullivan, Taegen, Mayer, Christina, Pavliv, Leo, Layzer, Juliana M, Lickliter, Jason, Sullenger, Bruce, Campbell, Bruce, Becker, Richard C

“…IntroductionVon Willebrand Factor (VWF) is a ubiquitous component of thrombi extracted by endovascular thrombectomy from patients with large vessel occlusion…”
Get full text

Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia by Lin, Tara L., Wood, Robyn, Ham, Tammy, Sullivan, Taegen, Dandawate, Prasad, Anant, Shrikant, Santaguida, Marianne T, Toren, Paul, Jensen, Roy A., Taylor, John A., Baltezor, Michael Jay, Dalton, Michael, Meyer, Fred, McBride, John, Umbreit, Jay Nicholas, McCulloch, William, Vanderlaag, Kathryn, Wagner, Joseph, Weir, Scott James, Smith, B. Douglas

“…TPS7078 Background: Fosciclopirox (CPX-POM) is a broad-spectrum anticancer agent being developed through a public-private partnership between CicloMed LLC and…”
Get full text

Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia by Lin, Tara L., Wood, Robyn, Ham, Tammy, Sullivan, Taegen, Bhattacharyya, Sangita, Dandawate, Prasad, Anant, Shrikant, Santaguida, Marianne T, Zhang, Na, Toren, Paul, Jensen, Roy A., Taylor, John A., Baltezor, Michael Jay, Dalton, Michael, McBride, John, Umbreit, Jay Nicholas, McCulloch, William, Vanderlaag, Kathryn, Wagner, Joseph, Weir, Scott James

“…TPS7069 Background: Fosciclopirox (F) is a γ-secretase inhibitor being developed for the treatment of acute myeloid leukemia (AML). Following intravenous (IV)…”
Get full text